Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
smile, Thanks for the info. If we get some positive news from Ani, a new analyst initiates coverage with a buy rating, or an existing analyst issues an upgrade, maybe we have a mini-short squeeze on the horizon. :) Best of good luck to you and all the rest of us retail shareholders!
jeff, you make very good points in regard to which I concur.
I'd, of course, be a dream come true for us, if the hypothesis you set forth (or something similar) ever becomes reality! In the meantime, I'll just remain hopeful. Thanks. :)
Re: CV & Breast Cancer related patent application:
If, as asserted, the application is part of the collateral used to secure the Citizens Bank loan, then said patent application presumably has (or potentially has) monetary value.
Otherwise its inclusion as collateral would serve no purpose in securing the loan.
Of course, per the discussions on this board pertaining to the patent application, its pendency, possible abandonment or refiling following abandonment, only time will tell whether or not there is value or potential value relating to the CV & Breast Cancer study results.
However, based on the aforementioned scenario, I continue to agree with the hypotheses set forth by JTFM.
All the best to all retail shareholders.
smile I hadn't noticed. Thanks for the information and insight. Now that I've thought about what you observed and concluded, I 100% concur. Best of good luck to you and all the rest of us retail shareholders!
JTFM, Your research and input, as always, are very much appreciated.
Hopefully, in the not too distant future, more investors will become aware of how undervalued ANIP currently appears to be compared to higher valuations accorded to other high growth publicly traded companies in relation to free cash flow!
jadite,
With respect to the senior convertible note deal, I'm as ignorant and lacking in understanding of the details and their implications as anyone. Otherwise, I share your sentiments. :)
Previously posted here I believe, but still pretty good analysis: https://finance.yahoo.com/news/does-ani-pharmaceuticals-inc-nasdaq-181913466.html
Thanks jadite. Like you, I hope today's improved price action continues with an even better day tomorrow! I think all of us deserve it!
FWIW, Zacks Investment Research currently has ANIP rated as a Buy.
I'm a subscriber to the service and only recently noticed they'd upgraded ANIP from a Neutral rating.
Their Buy rating of ANIP might not help but, of course, it can't hurt! :)
Just thought I'd mention the foregoing for anyone who might find it of interest.
Best of good luck to all shareholders.
Corporate Presentation May 2018: https://www.sec.gov/Archives/edgar/data/1023024/000114420418029074/tv494239_ex99-1.htm
tomhilsen, That's an excellent post!
I 100% agree with you regarding the valuation and that ANIP apparently is flying under the radar.
It's hard to believe, in this day and age of easy access to information, ANIP could be (IMHO) so extremely unappreciated and undervalued!
Article titled "Trump promised to bring pharma to justice. His speech sent drug stocks soaring"
Here's the link to the article: https://www.statnews.com/2018/05/11/trump-drug-pricing-speech-stocks/
P.S. I noticed one of our insiders has continued selling but still owns a huge chunk of shares.
ANIP, as we're aware, so far this year, has been a loser.
I checked and found the closing price on 12-29-2017 was $64.45, although the price jumped to $68.73 on January 2nd, the first day of trading this year.
Hopefully, the market doesn't know something negative that we're unaware of and tomorrow's ER and CC will be sufficiently good to reverse the 2018 downtrend.
Best of good luck to all ANIP shareholers!
Relative to IR's refusal to respond to inquiries about Libigel, the only reasonable conclusion I can reach is there's a non-disclosure agreement pertaining to Libigel. Until ANIP says something to the contrary and/or specifically discloses the status of Libigel, that is my belief. Good luck to all ANIP shareholders!
As we're aware, sometimes silence is more telling than a written or oral response to an inquiry.
The consistent silence by Ani regarding Libigel, considered in light of all the other circumstantial evidence you've uncovered and ably set-forth, reinforce my hope that a non-disclosure agreement does exist; and, consequently, I'm hopeful Libigel may at some point emerge as a viable drug.
Thank you for sharing your research, thoughts and insights in posts and articles you've written.
Among the entire universe of stocks (many of which are priced to perfection), I think I can reasonably conclude and believe ANIP is one of the most ignored, undervalued and oversold stocks that a person doing their own due diligence could find. JMHO
Best of good luck to all other ANIP shareholders!
Here's a link to ANIP's PR with a little more detail: http://www.anipharmaceuticals.com/aboutus_newsmedia_view.php?i=149
Catty thanks and here you go with link to and copy and paste of Seeking Alpha article:
https://seekingalpha.com/news/3350066-ani-pharmaceuticals-buying-assets-amneal-impax
"ANI Pharmaceuticals buying assets from Amneal, Impax
Apr. 27, 2018 7:13 PM ET|About: ANI Pharmaceuticals, Inc. (ANIP)|By: Jason Aycock, SA News Editor
ANI Pharmaceuticals (NASDAQ:ANIP) has signed definitive deals to acquire generic products and assets from Amneal Pharmaceuticals and Impax Laboratories (NASDAQ:IPXL) for cash.
Exact terms were undisclosed. Amneal and Impax are unloading the assets, which serve a combined current annual U.S. market of $1.7B, as part of an FTC-mandated divestiture required for their proposed business combination.
ANI gets a portfolio of five approved generic ANDAs and one pipeline product (Erythromycin IR tablets), as well as a license, supply and distribution deal for another pipeline product, Diclofenac-Misoprostol DR tablets, with a pending ANDA.
The transaction is expected to close in early May."
Seems apparent ANIP is inexplicably "mispriced for imperfection" vis-à-vis most other stocks that some experts say are "priced for perfection", especially if ANIP's current share price is considered in light of ANIP's 2018 earnings guidance of Adjusted non-GAAP diluted earnings per share of $5.43 to $6.08 (compared to $3.91 in 2017).
Hopefully, ANIP's share price will become more realistically priced sooner rather than much later.
Best of good luck to all shareholders and in particular to those who post on this board!
I agree with you and believe your statements and conclusions are logical, sound and, of course, reasonable... makes perfect sense to me.
Jeff,
I agree we don't have knowledge of direct evidence of the existence of a non-disclosure agreement. However, as we know, there's circumstantial evidence upon which one may hypothesize that such an agreement exists as JTFM has very ably demonstrated in setting forth his entire hypothesis regarding Libigel.
A great weekend to you and everyone else!
Jon,
You make some good points.
However, in regard to disclosing the filing a new drug application with the FDA or the re-submission of one, couldn't such a disclosure be prohibited under the terms of a non-disclosure agreement? I think the answer is yes. Of course, it's obvious the existence of a non-disclosure agreement (admittedly without direct evidence that such an agreement exists) is no more than an assumption based on the circumstances present,i.e., Ani's complete silence regarding Libigel, etc. upon which JTFM's hypothesis is based.
Why doesn't Ani simply inform inquiring shareholders specifically one way or the other regarding the status of Libigel, which would, of course, put the entire matter to rest?
Obviously, without Ani doing so, the status of Libigel is understandably left open for some shareholders to question and hypothesize.
Jeff,
I agree with everything you've stated.
With that said, as long as the company is silent about Libigel, IR is vague in its replies and/or non-responsive to clearly stated questions pertaining to the status of Libigel, and the CVRs remain on the company's website; I'm open to what JTFM has been saying particularly in regard to the possibility of the existence of a NDA, which I can only conclude is consistent with the foregoing.
Per Zacks Equity Research: Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock? FWIW, here's the link to the article dated March 14, 2018: https://finance.yahoo.com/news/value-investors-pick-ani-pharmaceuticals-135501556.html
Again, I apologize for another duplicate post. They were made from a lap top which might have a glitch of some type causing double posts. Anyway, I'm switching over to using a desk top that hopefully will eliminate my double posting. If not, I'll cease posting. :)
It'd be nice if ANI's presentation at Wednesday's Conference stirs up more investor interest and institutional buying. Also, maybe it'll provide impetus for analyst(s) to initiate coverage with buy rating(s).
It'd be nice if ANI's presentation at Wednesday's Conference stirs up more investor interest and institutional buying. Also, maybe it'll provide impetus for analyst(s) to initiate coverage with buy rating(s).
Opps sorry for my double post... not sure what I did wrong to cause it.
Jeff, I agree, in particular regarding our CEO's transactions. The SEC Form 4 filed today reflects the options he exercised resulted in his acquisition of 23,986 shares, the same number of shares he disposed of, with all these transactions occurring on March 1, 2018. The SEC Form 4 also reflects he still owns 209,983 shares, which @ today's closing price of $63.87 per share has a total value of $13.41 million dollars. That's a very sizable position in my opinion and causes no concern by me.
Jeff, I agree, in particular regarding our CEO's transactions. The SEC Form 4 filed today reflects the options he exercised resulted in his acquisition of 23,986 shares, the same number of shares he disposed of, with all these transactions occurring on March 1, 2018. The SEC Form 4 also reflects he still owns 209,983 shares, which @ today's closing price of $63.87 per share has a total value of $13.41 million dollars. That's a very sizable position in my opinion and causes no concern by me.
Consistently higher earnings growth is the primary reason I began buying the stock last year. I too can only shake my head with disbelief seeing the shares priced at about 10 times forward earnings! Hopefully, the market will reward us with a much more realistically higher price sooner than later. Best of good luck to all!
Nice positive comments re ANI. Thx!
Interesting IR reply. Thanks!
Thank you JTFM for your post!
Glad you remember it was Bio-T-gel that was written down last year.Thanks.
Very good question!
Per Seeking Alpha here's link to transcript of the CC: https://seekingalpha.com/article/4151231-ani-pharmaceuticals-anip-ceo-arthur-przybyl-q4-2017-results-earnings-call-transcript?part=single
"In addition, during the fourth quarter, we recognized a 900,000 non-cash write-off of our finite live non-core intangible asset. This intangible related to our NDA for testosterone gel, an asset that was acquired and accounted for in our 2013 merger with BioSante.
This asset was previously written down in the fourth quarter of last year. We have now officially discontinued this filing with the FDA and describe no further value on our balance sheet for this product."
Regarding the CVRs, as we're aware, the information pertaining to the CVRs is still on the Ani website: http://www.anipharmaceuticals.com/investors_cvrs.php
If LibiGel is dead, it seems that information would've been deleted. On the other hand, since that information is still on the website, wouldn't it be reasonable to conclude LibiGel may not be dead?
JTFM, Thank you for another great post! The specificity of facts and questions you enumerated in this most recent post (to which I made this reply), your other posts on message boards and in your published articles I find very interesting, thought provoking and an awesome basis for additional optimism concerning ANIP apart from which is publicly known. Hopefully, as ANIP shareholders, sooner rather than later, we'll have answers as you indicated. I very much appreciate the tremendous amount of fact gathering you've done, thought and insights in formulating all the questions you've posed, the information you've set forth, your time and effort involved and especially your sharing your work product with all of us in your articles and posts! Again, many thanks!